CR20210383A - Inhibidores de apol 1 y sus métodos de uso - Google Patents

Inhibidores de apol 1 y sus métodos de uso

Info

Publication number
CR20210383A
CR20210383A CR20210383A CR20210383A CR20210383A CR 20210383 A CR20210383 A CR 20210383A CR 20210383 A CR20210383 A CR 20210383A CR 20210383 A CR20210383 A CR 20210383A CR 20210383 A CR20210383 A CR 20210383A
Authority
CR
Costa Rica
Prior art keywords
same
methods
apol1
inhibitors
ndkd
Prior art date
Application number
CR20210383A
Other languages
English (en)
Inventor
Suganthini S Nanthakumar
Kevin Gagnon
Leslie A Dakin
Kan-Nian Hu
Ales Medek
Yi Shi
Muna Shrestha
Francois Denis
Elaine B Krueger
Faith Witkos
Jingrong Cao
Martine Hamel
Brian Ledford
Olivier Nicolas
Jon H Come
Warren A Dorsch
Anne Fortier
Peter Rose
Camil Sayegh
Tiansheng Wang
Michael Brodney
Timothy J Senter
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of CR20210383A publication Critical patent/CR20210383A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C07F7/0814—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring said ring is substituted at a C ring atom by Si
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C07F7/0816—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring said ring comprising Si as a ring atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/46—Phosphinous acids R2=P—OH; Thiophosphinous acids; Aminophosphines R2-P-NH2 including R2P(=O)H; derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
    • C07F9/65842—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

La descripción proporciona al menos una entidad seleccionada de compuestos de la fórmula (<strong>I</strong>), formas en estado sólido de ellos, composiciones que los comprenden y métodos que los usan, incluyendo el uso en el tratamiento de glomeruloesclerosis segmentaria focal (FSGS) y/o enfermedad renal no diabética (NDKD).
CR20210383A 2018-12-17 2019-12-17 Inhibidores de apol 1 y sus métodos de uso CR20210383A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862780667P 2018-12-17 2018-12-17
PCT/US2019/066746 WO2020131807A1 (en) 2018-12-17 2019-12-17 Inhibitors of apol1 and methods of using same

Publications (1)

Publication Number Publication Date
CR20210383A true CR20210383A (es) 2021-09-22

Family

ID=69182627

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20210383A CR20210383A (es) 2018-12-17 2019-12-17 Inhibidores de apol 1 y sus métodos de uso

Country Status (23)

Country Link
US (2) US11618746B2 (es)
EP (1) EP3897833A1 (es)
JP (1) JP2022515369A (es)
KR (1) KR20210116483A (es)
CN (1) CN113453760A (es)
AR (1) AR116913A1 (es)
AU (1) AU2019405477A1 (es)
BR (1) BR112021011564A2 (es)
CA (1) CA3121910A1 (es)
CL (1) CL2021001561A1 (es)
CO (1) CO2021009053A2 (es)
CR (1) CR20210383A (es)
DO (1) DOP2021000116A (es)
EC (1) ECSP21052184A (es)
IL (1) IL283592A (es)
JO (3) JOP20210131A1 (es)
MA (1) MA54538A (es)
MX (1) MX2021007152A (es)
PE (1) PE20212302A1 (es)
SG (1) SG11202105769XA (es)
TW (1) TW202039471A (es)
UY (1) UY38514A (es)
WO (1) WO2020131807A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA54538A (fr) 2018-12-17 2021-10-27 Vertex Pharma Inhibiteurs d'apol1 et leurs procédés d'utilisation
AU2021213758A1 (en) * 2020-01-29 2022-09-01 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and methods of using same
WO2021158666A1 (en) * 2020-02-04 2021-08-12 Vertex Pharmaceuticals Incorporated Solid forms of apol1 inhibitor and methods of using same
IL296035A (en) 2020-03-06 2022-10-01 Vertex Pharma Treatment methods for apol-1 dependent focal segmental tuberous sclerosis
CR20230132A (es) 2020-08-26 2023-06-27 Vertex Pharma Inhibidores de apol1 y métodos para usar los mismos
AU2022334580A1 (en) * 2021-08-26 2024-03-07 Vertex Pharmaceuticals Incorporated Solid forms of spirotricyclic apol1 inhibitors and methods of using same
WO2023101981A1 (en) * 2021-11-30 2023-06-08 Vertex Pharmaceuticals Incorporated Spirocyclic inhibitors of apol1 and methods of using same
WO2023141432A2 (en) 2022-01-18 2023-07-27 Maze Therapeutics, Inc. Apol1 inhibitors and methods of use
WO2023154344A1 (en) * 2022-02-08 2023-08-17 Vertex Pharmaceuticals Incorporated 2-methyl-4',5'-dihydrospiro[piperidine-4,7'-thieno[2,3-c]pyran] derivatives as inhibitors of apol1 and methods of using same
WO2023194895A1 (en) 2022-04-06 2023-10-12 Glaxosmithkline Intellectual Property Development Limited Pyrrol derivatives as inhibitors of apolipoprotein l-1
WO2024040235A1 (en) * 2022-08-19 2024-02-22 Maze Therapeutics, Inc. Apol1 inhibitors and methods of use

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2801585B1 (fr) 1999-11-25 2002-02-15 Fournier Ind & Sante Nouveaux antagonistes des recepteurs de l'ii-8
EP1324985A4 (en) 2000-10-02 2004-10-06 Merck & Co Inc PRENYL PROTEIN TRANSFERASE INHIBITORS
FR2824827B1 (fr) 2001-05-17 2004-02-13 Fournier Lab Sa Nouveaux derives de 5-phenyl-1h-indole antagoniste des recepteurs de l'interleukine-8
FR2824826B1 (fr) 2001-05-17 2003-11-07 Fournier Lab Sa Nouveaux derives de 5-cyano-1h-indole antagonistes des recepteurs de l'interleukine-8
MXPA04004657A (es) 2001-11-14 2004-08-13 Teva Pharma Formas amorfas y cristalinas de potasio de losartan y proceso para su preparacion.
AU2003237593A1 (en) * 2002-06-05 2003-12-22 Natco Pharma Limited Process for the preparation of 4-(4-fluorobenzoyl) butyric acid
US8053440B2 (en) * 2007-02-01 2011-11-08 Resverlogix Corporation Compounds for the prevention and treatment of cardiovascular diseases
JP5323834B2 (ja) 2007-08-17 2013-10-23 エルジー・ライフ・サイエンシーズ・リミテッド 細胞壊死阻害剤としてのインドール化合物
JP5685203B2 (ja) 2009-05-29 2015-03-18 ラクオリア創薬株式会社 カルシウムチャネル遮断薬またはナトリウムチャネル遮断薬としてのアリール置換カルボキサミド誘導体
US10130632B2 (en) 2012-11-27 2018-11-20 Beth Israel Deaconess Medical Center, Inc. Methods for treating renal disease
US9850203B2 (en) * 2013-09-26 2017-12-26 Pharmakea, Inc. Autotaxin inhibitor compounds
WO2016029310A1 (en) 2014-08-27 2016-03-03 The Governing Council Of The University Of Toronto Cannabinoid type 1 receptor modulators
US10654838B2 (en) 2014-10-08 2020-05-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Aminopyridine compounds useful as inhibitors of protein prenylation
ES2865199T3 (es) 2015-08-27 2021-10-15 Pfizer Compuestos de heteroarilo o arilo condensados bicíclicos como moduladores de IRAK4
MA54538A (fr) 2018-12-17 2021-10-27 Vertex Pharma Inhibiteurs d'apol1 et leurs procédés d'utilisation
AU2021213758A1 (en) 2020-01-29 2022-09-01 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and methods of using same
WO2021158666A1 (en) 2020-02-04 2021-08-12 Vertex Pharmaceuticals Incorporated Solid forms of apol1 inhibitor and methods of using same
IL296035A (en) * 2020-03-06 2022-10-01 Vertex Pharma Treatment methods for apol-1 dependent focal segmental tuberous sclerosis
EP4165022A1 (en) 2020-06-12 2023-04-19 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and use of the same
WO2021252863A1 (en) 2020-06-12 2021-12-16 Vertex Pharmaceuticals Incorporated Solid forms of apol1 inhibitor and using the same
WO2021252849A1 (en) 2020-06-12 2021-12-16 Vertex Pharmaceuticals Incorporated Inhibitors of apol1 and use of the same
CR20230132A (es) 2020-08-26 2023-06-27 Vertex Pharma Inhibidores de apol1 y métodos para usar los mismos

Also Published As

Publication number Publication date
CO2021009053A2 (es) 2021-08-09
US20200377479A1 (en) 2020-12-03
AU2019405477A1 (en) 2021-06-24
US20230271945A1 (en) 2023-08-31
IL283592A (en) 2021-07-29
CN113453760A (zh) 2021-09-28
EP3897833A1 (en) 2021-10-27
PE20212302A1 (es) 2021-12-10
MX2021007152A (es) 2021-11-03
JOP20210129A1 (ar) 2023-01-30
KR20210116483A (ko) 2021-09-27
JOP20210131A1 (ar) 2023-01-30
AR116913A1 (es) 2021-06-23
JP2022515369A (ja) 2022-02-18
ECSP21052184A (es) 2021-08-31
UY38514A (es) 2020-07-31
TW202039471A (zh) 2020-11-01
DOP2021000116A (es) 2021-09-30
MA54538A (fr) 2021-10-27
US11618746B2 (en) 2023-04-04
JOP20210130A1 (ar) 2023-01-30
CA3121910A1 (en) 2020-06-25
SG11202105769XA (en) 2021-07-29
CL2021001561A1 (es) 2021-11-26
WO2020131807A1 (en) 2020-06-25
BR112021011564A2 (pt) 2021-08-31

Similar Documents

Publication Publication Date Title
JOP20210130A1 (ar) مثبطات apol1 وطرق استخدامها
CR20200347A (es) Inhibidores pd-1/pd-l1
CR20200376A (es) Inhibidores de cd73
GEP20237506B (en) Pcsk9 antagonist compounds
CO2021005884A2 (es) Moduladores de la alfa-1 antitripsina
EA201891268A1 (ru) Соединения, которые можно применять в качестве ингибиторов киназы
EA202191084A1 (ru) Соединения пиридазинонов и их применения
GEP20227443B (en) Magl inhibitors
EA202092086A1 (ru) Ингибиторы аргиназы
MX2021005348A (es) Compuestos de piridazinonas y usos de los mismos.
EA202190073A1 (ru) Композиции и способы лечения видов гемоглобинопатии и талассемии
PH12021500008A1 (en) Transglutaminase 2 (tg2) inhibitors
MX2023002269A (es) Inhibidores de apol1 y metodos para usar los mismos.
MX2021003187A (es) Inhibición de la peptidasa específica de ubiquitina 9x.
MX2022007841A (es) Degradadores del regulador dependiente de actina asociado a la matriz relacionado con el complejo switch/sacarosa no fermentable de la subfamilia a de la cromatina (smarca)y usos de los mismos.
MX2020012281A (es) Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas.
MX2021003843A (es) Inhibidores de la interaccion yap/taz-tead y su uso en el tratamiento del cancer.
CL2020003010A1 (es) Moduladores de la expresión de apol1
WO2019026065A3 (en) Novel braf inhibitors and use thereof for treatment of cutaneous reactions
CL2022001452A1 (es) Inhibidores de masp-2 y métodos de uso.
MX2021010603A (es) Inhibidores de caspasa y metodos de uso de los mismos.
JOP20210143A1 (ar) تركيبات وطرق لعلاج ومنع التصلب الجانبي الضموري
EA201891240A1 (ru) 1,3,4-тиадиазольные соединения и их применение в лечении рака
WO2020102243A3 (en) In-flow photooxygenation of aminothienopyridinones generates novel ptp4a3 phosphatase inhibitors
EA202190766A1 (ru) Иммуномодуляторы, их композиции и способы применения